VolitionRx Limited (NYSE American: VNRX) released a corporate update detailing recent clinical and commercial advancements across its diagnostics portfolio. The company announced the submission of a feline lymphoma manuscript, which is linked to a potential $5 million milestone payment. This development underscores VolitionRx's commitment to expanding its veterinary diagnostics offerings and generating value through strategic milestones.
In addition to the manuscript submission, VolitionRx reported continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. These conversations aim to expand the reach of VolitionRx's proprietary Nu.Q technology, which focuses on detecting nucleosomes and their modifications for early disease detection and monitoring. The company's ability to attract interest from multiple industry players highlights the perceived value of its epigenetic platform.
VolitionRx also provided updates on its human diagnostics pipeline. The Capture-Seq cancer detection platform is progressing through validation studies, with the goal of enhancing sensitivity and specificity for multiple cancer types. The Nu.Q NETs program, focused on sepsis, is expanding as the company explores the role of neutrophil extracellular traps in inflammatory diseases. Additionally, VolitionRx is advancing efforts to secure reimbursement in France for its lung cancer assay, a critical step toward routine clinical use in that market.
These developments reflect VolitionRx's strategy to commercialize simple, cost-effective blood tests for early detection and monitoring of diseases. The company operates through subsidiaries and conducts research and development in Belgium, with additional offices in the U.S. and London. For more information, visit the company's website at https://volition.com/.
The full press release can be accessed at https://ibn.fm/nX9FK.
